Advertisement
Screener

VERTEX PHARMACEUTICALS INC / MA (VRTX) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

VERTEX PHARMACEUTICALS INC / MA Selling, General and Administrative Expense

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Selling, General and Administrative Expense of $582.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04

  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for the quarter ending 2026-06-30 was $582.20M, a 37.12% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for the quarter ending 2026-03-31 was $493.70M, a 24.55% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for the quarter ending 2025-12-31 was $487.00M, a 28.97% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for the quarter ending 2025-09-30 was $445.10M, a 19.71% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for fiscal 2025 was $1.75B, a 19.72% increase from fiscal 2024.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for fiscal 2024 was $1.46B, a 28.83% increase from fiscal 2023.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for fiscal 2023 was $1.14B, a 20.31% increase from fiscal 2022.
  • VERTEX PHARMACEUTICALS INC / MA selling, general and administrative expense for fiscal 2022 was $944.70M, a 12.45% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 3 month as first filedSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 6 month as first filedSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 9 month as first filedSelling, General and Administrative Expense 12 monthSelling, General and Administrative Expense 12 month as first filed
2026-06-30$582.20M
10-Q · filed 2026-08-04
$1.08B
10-Q · filed 2026-08-04
$1.56B
derived: sum of 3 quarters · filed 2026-08-04
$2.01B
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$493.70M
10-Q · filed 2026-05-05
$980.70M
derived: sum of 2 quarters · filed 2026-05-05
$1.43B
derived: sum of 3 quarters · filed 2026-05-05
$1.85B
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$487.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$932.10M
derived: sum of 2 quarters · filed 2026-02-13
$1.36B
derived: sum of 3 quarters · filed 2026-08-04
$1.75B
10-K · filed 2026-02-13
2025-09-30$445.10M
10-Q · filed 2025-11-04
$869.70M
derived: sum of 2 quarters · filed 2026-08-04
$1.27B
10-Q · filed 2025-11-04
$1.64B
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$424.60M
10-Q · filed 2026-08-04
$821.00M
10-Q · filed 2026-08-04
$1.20B
derived: sum of 3 quarters · filed 2026-08-04
$1.57B
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$396.40M
10-Q · filed 2026-05-05
$774.00M
derived: sum of 2 quarters · filed 2026-05-05
$1.15B
derived: sum of 3 quarters · filed 2026-05-05
$1.52B
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$377.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$749.40M
derived: sum of 2 quarters · filed 2026-02-13
$1.12B
derived: sum of 3 quarters · filed 2026-02-13
$1.46B
10-K · filed 2026-02-13
2024-09-30$371.80M
10-Q · filed 2025-11-04
$744.00M
derived: sum of 2 quarters · filed 2025-11-04
$1.09B
10-Q · filed 2025-11-04
$1.46B
derived: sum of 4 quarters · filed 2026-02-13
2024-06-30$372.20M
10-Q · filed 2025-08-05
$714.90M
10-Q · filed 2025-08-05
$1.08B
derived: sum of 3 quarters · filed 2026-02-13
$1.35B
derived: sum of 4 quarters · filed 2026-02-13
2024-03-31$342.70M
10-Q · filed 2025-05-06
$711.80M
derived: sum of 2 quarters · filed 2026-02-13
$975.60M
derived: sum of 3 quarters · filed 2026-02-13
$1.24B
derived: sum of 4 quarters · filed 2026-02-13
2023-12-31$369.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$632.90M
derived: sum of 2 quarters · filed 2026-02-13
$895.50M
derived: sum of 3 quarters · filed 2026-02-13
$1.14B
10-K · filed 2026-02-13
2023-09-30$263.80M
10-Q · filed 2024-11-05
$526.40M
derived: sum of 2 quarters · filed 2024-11-05
$767.50M
10-Q · filed 2024-11-05
$1.03B
derived: sum of 4 quarters · filed 2025-02-13
2023-06-30$262.60M
10-Q · filed 2024-08-02
$503.70M
10-Q · filed 2024-08-02
$771.10M
derived: sum of 3 quarters · filed 2025-02-13
$1.02B
derived: sum of 4 quarters · filed 2025-02-13
2023-03-31$241.10M
10-Q · filed 2024-05-07
$508.50M
derived: sum of 2 quarters · filed 2025-02-13
$755.30M
derived: sum of 3 quarters · filed 2025-02-13
$970.60M
derived: sum of 4 quarters · filed 2025-02-13
2022-12-31$267.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13
$514.20M
derived: sum of 2 quarters · filed 2025-02-13
$729.50M
derived: sum of 3 quarters · filed 2025-02-13
$944.70M
10-K · filed 2025-02-13
2022-09-30$246.80M
10-Q · filed 2023-11-07
$462.10M
derived: sum of 2 quarters · filed 2023-11-07
$677.30M
10-Q · filed 2023-11-07
$932.50M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30$215.30M
10-Q · filed 2023-08-02
$430.50M
10-Q · filed 2023-08-02
$685.70M
derived: sum of 3 quarters · filed 2024-02-15
$883.90M
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31$215.20M
10-Q · filed 2023-05-02
$470.40M
derived: sum of 2 quarters · filed 2024-02-15
$668.60M
derived: sum of 3 quarters · filed 2024-02-15
$863.20M
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31$255.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
$453.40M
derived: sum of 2 quarters · filed 2024-02-15
$648.00M
derived: sum of 3 quarters · filed 2024-02-15
$840.10M
10-K · filed 2024-02-15
2021-09-30$198.20M
10-Q · filed 2022-10-28
$198.19M
10-Q · filed 2021-11-03
$392.80M
derived: sum of 2 quarters · filed 2022-10-28
$584.90M
10-Q · filed 2022-10-28
$584.93M
10-Q · filed 2021-11-03
$796.74M
derived: sum of 4 quarters · filed 2022-10-28
2021-06-30$194.60M
10-Q · filed 2022-08-05
$194.67M
10-Q · filed 2021-07-30
$386.70M
10-Q · filed 2022-08-05
$386.75M
10-Q · filed 2021-07-30
$598.54M
derived: sum of 3 quarters · filed 2022-08-05
$783.09M
derived: sum of 4 quarters · filed 2022-08-05
2021-03-31$192.10M
10-Q · filed 2022-05-06
$192.08M
10-Q · filed 2021-04-30
$403.94M
derived: sum of 2 quarters · filed 2022-05-06
$588.49M
derived: sum of 3 quarters · filed 2022-05-06
$780.30M
derived: sum of 4 quarters · filed 2022-05-06
2020-12-31$211.84M
10-K · filed 2021-02-11
$396.39M
derived: sum of 2 quarters · filed 2021-11-03
$588.20M
derived: sum of 3 quarters · filed 2021-11-03
$770.50M
10-K · filed 2023-02-10
$770.46M
10-K · filed 2021-02-11
2020-09-30$184.55M
10-Q · filed 2021-11-03
$376.36M
derived: sum of 2 quarters · filed 2021-11-03
$558.61M
10-Q · filed 2021-11-03
$753.89M
derived: sum of 4 quarters · filed 2021-11-03
2020-06-30$191.80M
10-Q · filed 2021-07-30
$374.06M
10-Q · filed 2021-07-30
$569.34M
derived: sum of 3 quarters · filed 2021-07-30
$729.01M
derived: sum of 4 quarters · filed 2021-07-30
2020-03-31$182.26M
10-Q · filed 2021-04-30
$377.54M
derived: sum of 2 quarters · filed 2021-04-30
$537.21M
derived: sum of 3 quarters · filed 2021-04-30
$693.71M
derived: sum of 4 quarters · filed 2021-04-30
2019-12-31$195.28M
10-K · filed 2021-02-11
$354.95M
derived: sum of 2 quarters · filed 2021-02-11
$511.45M
derived: sum of 3 quarters · filed 2021-02-11
$658.50M
10-K · filed 2022-02-09
$658.50M
10-K · filed 2020-02-13
2019-09-30$159.67M
10-K · filed 2021-02-11
$316.18M
derived: sum of 2 quarters · filed 2021-02-11
$463.22M
10-Q · filed 2020-10-30
$616.43M
derived: sum of 4 quarters · filed 2021-02-11
2019-06-30$156.50M
10-K · filed 2021-02-11
$303.55M
10-Q · filed 2020-07-31
$456.76M
derived: sum of 3 quarters · filed 2021-02-11
$594.05M
derived: sum of 4 quarters · filed 2021-02-11
2019-03-31$147.04M
10-K · filed 2021-02-11
$300.25M
derived: sum of 2 quarters · filed 2021-02-11
$437.55M
derived: sum of 3 quarters · filed 2021-02-11
$574.85M
derived: sum of 4 quarters · filed 2021-02-11
2018-12-31$153.21M
10-K · filed 2020-02-13
$290.50M
derived: sum of 2 quarters · filed 2020-02-13
$427.81M
derived: sum of 3 quarters · filed 2020-02-13
$557.62M
10-K · filed 2021-02-11
2018-09-30$137.29M
10-K · filed 2020-02-13
$274.60M
derived: sum of 2 quarters · filed 2020-02-13
$404.41M
10-Q · filed 2019-10-31
$539.20M
derived: sum of 4 quarters · filed 2020-02-13
2018-06-30$137.30M
10-K · filed 2020-02-13
$267.11M
10-Q · filed 2019-08-01
$401.90M
derived: sum of 3 quarters · filed 2020-02-13
$522.62M
derived: sum of 4 quarters · filed 2020-02-13
2018-03-31$129.81M
10-K · filed 2020-02-13
$264.60M
derived: sum of 2 quarters · filed 2020-02-13
$385.31M
derived: sum of 3 quarters · filed 2020-02-13
$512.56M
derived: sum of 4 quarters · filed 2020-02-13
2017-12-31$134.79M
10-K · filed 2019-02-13
$255.50M
derived: sum of 2 quarters · filed 2019-02-13
$382.75M
derived: sum of 3 quarters · filed 2019-02-13
$496.08M
10-K · filed 2020-02-13
2017-09-30$120.71M
10-K · filed 2019-02-13
$247.96M
derived: sum of 2 quarters · filed 2019-02-13
$361.29M
10-Q · filed 2018-10-25
$471.19M
derived: sum of 4 quarters · filed 2019-02-13
2017-06-30$127.25M
10-K · filed 2019-02-13
$240.57M
10-Q · filed 2018-07-26
$350.48M
derived: sum of 3 quarters · filed 2019-02-13
$456.54M
derived: sum of 4 quarters · filed 2019-02-13
2017-03-31$113.33M
10-K · filed 2019-02-13
$223.23M
derived: sum of 2 quarters · filed 2019-02-13
$329.29M
derived: sum of 3 quarters · filed 2019-02-13
$440.94M
derived: sum of 4 quarters · filed 2019-02-13
2016-12-31$109.91M
10-K · filed 2018-02-15
$215.96M
derived: sum of 2 quarters · filed 2018-02-15
$327.62M
derived: sum of 3 quarters · filed 2018-02-15
$432.83M
10-K · filed 2019-02-13
2016-09-30$106.06M
10-K · filed 2018-02-15
$217.71M
derived: sum of 2 quarters · filed 2018-02-15
$322.92M
10-Q · filed 2017-10-30
$419.47M
derived: sum of 4 quarters · filed 2018-02-15
2016-06-30$111.65M
10-K · filed 2018-02-15
$216.87M
10-Q · filed 2017-07-28
$313.42M
derived: sum of 3 quarters · filed 2018-02-15
$413.19M
derived: sum of 4 quarters · filed 2018-02-15
2016-03-31$105.21M
10-K · filed 2018-02-15
$201.76M
derived: sum of 2 quarters · filed 2018-02-15
$301.54M
derived: sum of 3 quarters · filed 2018-02-15
$395.93M
derived: sum of 4 quarters · filed 2018-02-15
2015-12-31$96.55M
10-K · filed 2017-02-23
$196.32M
derived: sum of 2 quarters · filed 2017-02-23
$290.71M
derived: sum of 3 quarters · filed 2017-02-23
$376.57M
10-K · filed 2018-02-15
2015-09-30$99.77M
10-K · filed 2017-02-23
$194.17M
derived: sum of 2 quarters · filed 2017-02-23
$280.03M
10-Q · filed 2016-10-31
$358.55M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30$94.39M
10-K · filed 2017-02-23
$180.25M
10-Q · filed 2016-08-01
$258.78M
derived: sum of 3 quarters · filed 2017-02-23
$334.00M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31$85.86M
10-K · filed 2017-02-23
$164.39M
derived: sum of 2 quarters · filed 2017-02-23
$239.61M
derived: sum of 3 quarters · filed 2017-02-23
$317.06M
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31$78.53M
10-K · filed 2016-02-16
$153.75M
derived: sum of 2 quarters · filed 2016-02-16
$231.20M
derived: sum of 3 quarters · filed 2016-02-16
$305.41M
10-K · filed 2017-02-23
2014-09-30$75.22M
10-K · filed 2016-02-16
$152.67M
derived: sum of 2 quarters · filed 2016-02-16
$226.88M
10-Q · filed 2015-10-30
$299.94M
derived: sum of 4 quarters · filed 2016-02-16
2014-06-30$77.45M
10-K · filed 2016-02-16
$151.66M
10-Q · filed 2015-08-04
$224.71M
derived: sum of 3 quarters · filed 2016-02-16
$311.14M
derived: sum of 4 quarters · filed 2016-02-16
2014-03-31$74.21M
10-K · filed 2016-02-16
$147.27M
derived: sum of 2 quarters · filed 2016-02-16
$233.69M
derived: sum of 3 quarters · filed 2016-02-16
$338.77M
derived: sum of 4 quarters · filed 2016-02-16
2013-12-31$73.06M
10-K · filed 2015-02-13
$75.19M
10-K · filed 2014-02-11
$159.48M
derived: sum of 2 quarters · filed 2015-02-13
$264.56M
derived: sum of 3 quarters · filed 2015-02-13
$356.19M
10-K · filed 2016-02-16
$362.34M
10-K · filed 2014-02-11
2013-09-30$86.43M
10-K · filed 2015-02-13
$87.75M
10-Q · filed 2013-11-07
$191.51M
derived: sum of 2 quarters · filed 2015-02-13
$283.13M
10-Q · filed 2014-11-06
$287.15M
10-Q · filed 2013-11-07
$393.58M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30$105.08M
10-K · filed 2015-02-13
$106.52M
10-Q · filed 2013-08-02
$199.40M
10-Q · filed 2014-07-31
$307.16M
derived: sum of 3 quarters · filed 2015-02-13
$404.84M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31$91.63M
10-K · filed 2015-02-13
$92.88M
10-Q · filed 2013-05-08
$202.08M
derived: sum of 2 quarters · filed 2015-02-13
$299.76M
derived: sum of 3 quarters · filed 2015-02-13
$417.27M
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31$110.45M
10-K · filed 2014-02-11
$208.14M
derived: sum of 2 quarters · filed 2014-02-11
$325.65M
derived: sum of 3 quarters · filed 2014-02-11
$432.68M
10-K · filed 2015-02-13
$436.80M
10-K · filed 2013-03-01
2012-09-30$97.68M
10-K · filed 2014-02-11
$215.20M
derived: sum of 2 quarters · filed 2014-02-11
$326.34M
10-Q · filed 2013-11-07
$448.23M
derived: sum of 4 quarters · filed 2014-02-11
2012-06-30$117.51M
10-K · filed 2014-02-11
$228.66M
10-Q · filed 2013-08-02
$350.54M
derived: sum of 3 quarters · filed 2014-02-11
$461.19M
derived: sum of 4 quarters · filed 2014-02-11
2012-03-31$111.15M
10-K · filed 2014-02-11
$233.03M
derived: sum of 2 quarters · filed 2014-02-11
$343.68M
derived: sum of 3 quarters · filed 2014-02-11
$440.34M
derived: sum of 4 quarters · filed 2014-02-11
2011-12-31$121.88M
10-K · filed 2013-03-01
$232.53M
derived: sum of 2 quarters · filed 2013-03-01
$329.20M
derived: sum of 3 quarters · filed 2013-03-01
$400.72M
10-K · filed 2014-02-11
2011-09-30$110.65M
10-K · filed 2013-03-01
$207.32M
derived: sum of 2 quarters · filed 2013-03-01
$278.84M
10-Q · filed 2012-11-06
$341.32M
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30$96.66M
10-K · filed 2013-03-01
$168.19M
10-Q · filed 2012-08-08
$230.66M
derived: sum of 3 quarters · filed 2013-03-01
$279.52M
derived: sum of 4 quarters · filed 2013-03-01
2011-03-31$71.52M
10-K · filed 2013-03-01
$134.00M
derived: sum of 2 quarters · filed 2013-03-01
$182.86M
derived: sum of 3 quarters · filed 2013-03-01
$223.77M
derived: sum of 4 quarters · filed 2013-03-01
2010-12-31$62.48M
10-K · filed 2012-02-22
$111.33M
derived: sum of 2 quarters · filed 2012-02-22
$152.25M
derived: sum of 3 quarters · filed 2012-02-22
$187.80M
10-K · filed 2013-03-01
2010-09-30$48.85M
10-K · filed 2012-02-22
$89.77M
derived: sum of 2 quarters · filed 2012-02-22
$125.32M
10-Q · filed 2011-11-03
$157.90M
derived: sum of 4 quarters · filed 2012-02-22
2010-06-30$40.91M
10-K · filed 2012-02-22
$76.47M
10-Q · filed 2011-08-09
$109.04M
derived: sum of 3 quarters · filed 2012-02-22
$145.61M
derived: sum of 4 quarters · filed 2012-02-22
2010-03-31$35.55M
10-K · filed 2012-02-22
$68.13M
derived: sum of 2 quarters · filed 2012-02-22
$104.70M
derived: sum of 3 quarters · filed 2012-02-22
$137.22M
derived: sum of 4 quarters · filed 2012-02-22
2009-12-31$32.57M
10-K · filed 2011-02-17
$69.15M
derived: sum of 2 quarters · filed 2011-02-17
$101.67M
derived: sum of 3 quarters · filed 2011-02-17
$130.19M
10-K · filed 2012-02-22
2009-09-30$36.57M
10-K · filed 2011-02-17
$69.10M
derived: sum of 2 quarters · filed 2011-02-17
$97.62M
10-Q · filed 2010-10-28
2009-06-30$32.53M
10-K · filed 2011-02-17
$61.05M
10-Q · filed 2010-08-03
2009-03-31$28.52M
10-K · filed 2011-02-17
2008-12-31$101.29M
10-K · filed 2011-02-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64